| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
55,671,000 |
| Market
Cap: |
78.22(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.2 - $11.21 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Marinus Pharmaceuticals is a pharmaceutical company focused on developing and commercializing products for patients suffering from rare genetic epilepsies and other seizure disorders. The U.S Food and Drug Administration approved the use of ZTALMY® (ganaxolone) oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients two years of age and older. Ganaxolone is being developed in formulations for various routes of administration: intravenous and oral. Ganaxolone acts at both synaptic and extrasynaptic gamma-aminobutyric acid type A receptors, a target known for its anti-seizure, antidepressant and anxiolytic potential.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
21,803 |
21,803 |
38,528 |
41,369 |
| Total Sell Value |
$215,409 |
$215,409 |
$374,962 |
$393,504 |
| Total People Sold |
5 |
5 |
5 |
8 |
| Total Sell Transactions |
5 |
5 |
15 |
18 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hulihan Joseph |
Chief Medical Officer |
• – – |
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
7,718 |
24,868 |
|
- |
|
| Ezickson Elan |
Director |
– • – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
2,750 |
|
- |
|
| Pfanstiel Steven |
Chief Financial Officer |
• – – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
16,550 |
16,550 |
|
- |
|
| Austin Charles |
Director |
– • – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
2,750 |
|
- |
|
| Arroyo Santiago |
Director |
– • – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
2,750 |
|
- |
|
| Mayleben Timothy M |
Director |
– • – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
13,875 |
|
- |
|
| Nochur Sara |
Director |
– • – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
2,750 |
|
- |
|
| Fischer Seth H.z. |
Director |
– • – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
3,444 |
|
- |
|
| Dougherty Michael R |
Director |
– • – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
3,312 |
|
- |
|
| Manning Martha E |
VP Gen Counsel and Corp Sec. |
• – – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
12,867 |
12,867 |
|
- |
|
| Vitullo Nicole |
Director |
– • – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
6,442 |
|
- |
|
| Hulihan Joseph |
Chief Medical Officer |
• – – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
17,150 |
17,150 |
|
- |
|
| Braunstein Scott |
Chief Executive Officer |
• • – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
42,900 |
67,900 |
|
- |
|
| Vitullo Nicole |
Director |
– • – |
2021-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
2,717 |
3,692 |
|
- |
|
| Vitullo Nicole |
Director |
– • – |
2021-03-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(17,804) |
0 |
|
- |
|
| Vitullo Nicole |
Director |
– • – |
2021-03-15 |
4 |
S |
$15.87 |
$67,448 |
I/I |
(4,250) |
0 |
|
-2% |
|
| Vitullo Nicole |
Director |
– • – |
2021-03-12 |
4 |
A |
$0.00 |
$0 |
I/I |
6,192 |
6,192 |
|
- |
|
| Vitullo Nicole |
Director |
– • – |
2021-03-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(619,221) |
0 |
|
- |
|
| Smith Edward F |
Former VP, CFO & Treasurer |
• – – |
2021-03-09 |
4 |
AS |
$17.80 |
$718,337 |
D/D |
(40,356) |
13,288 |
|
-16% |
|
| Smith Edward F |
Former VP, CFO & Treasurer |
• – – |
2021-03-09 |
4 |
OE |
$4.16 |
$149,456 |
D/D |
35,927 |
53,644 |
|
- |
|
| Smith Edward F |
CFO |
• – – |
2020-01-30 |
4 |
S |
$2.05 |
$4,879 |
D/D |
(2,380) |
17,717 |
|
-24% |
|
| Braunstein Scott |
Chief Executive Officer |
• • – |
2019-12-13 |
4 |
B |
$1.25 |
$125,000 |
D/D |
100,000 |
100,000 |
2.81 |
- |
|
| Smith Edward F |
CFO |
• – – |
2019-05-16 |
4 |
AS |
$5.03 |
$121,781 |
D/D |
(24,211) |
20,097 |
|
- |
|
| Cashman Christopher Michael |
CEO |
• • – |
2019-03-18 |
4 |
OE |
$1.04 |
$32,928 |
D/D |
31,662 |
271,423 |
|
- |
|
| Smith Edward F |
CFO |
• – – |
2019-01-29 |
4 |
S |
$3.06 |
$7,626 |
D/D |
(2,492) |
44,308 |
|
- |
|
129 Records found
|
|
Page 3 of 6 |
|
|
0.01 (1.06%) 
